Meridian Bioscience Announces Better-than-expected Preliminary First Quarter Fiscal 2021 Revenue Results

NEXT STORY
Adjustment of period for trading in subscription rights and interim shares in Active Biotech’s rights issue
PREV STORY
Translate Bio Announces Timing of Interim Results from mRNA Therapeutic Clinical Trial in Patients with Cystic Fibrosis; Data Expected in Early Q2 2021
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Optinose Expands Leadership Team with Key Hires

YARDLEY, Pa., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused ...

author_avatar
NASDAQ Market News

Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2018 and Operational Progress

author_avatar
NASDAQ Market News

Phase 2 Results on AKCEA-APO(a)-LRx Presented in Late-Breaking Clinical Trial Presentation at AHA Scientific Sessions

Approximately 98% of patients receiving highest dose achieved reductions in Lp(a) levels below the ...

author_avatar
NASDAQ Market News